Skip to main content
. Author manuscript; available in PMC: 2019 Aug 19.
Published in final edited form as: Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun 17;1864(10):1363–1374. doi: 10.1016/j.bbalip.2019.06.011

Fig. 4. Role of lipolytic products in the antioxidative capacity of EL-HDL.

Fig. 4

EV-HDL and EL-HDL were prepared in the absence (w/o BSA) or presence (w/ BSA) of 4% BSA followed by ultracentrifugation and FPLC. (A) LPC and (B) FA contents were determined by MS. LDL, EV-HDL and EL-HDL (the latter two prepared in the presence of 4% BSA) were incubated either individually or in the indicated combinations with 2 μmol/L CuCl2 at 37 °C followed by reaction termination after 120 min. (C) The formation of conjugated dienes was monitored at 234 nm. (D) MDA levels were measured in the reaction mixture obtained after 120 min by HPLC. (E) Lag phase and (F) MDA ratios of EV-HDL and EL-HDL prepared w/o or w/ 4% BSA. Results are means + SEM of 4 independent modifications of human HDL. The indicated differences in (A) and (B), as well as between EV-HDL and EL-HDL (with or without LDL) (C, D), and between w/o BSA and w/ BSA (E,F) were analyzed by two-tailed unpaired t-test followed by Bonferroni correction for multiple comparison (*P < 0.05, **P < 0.01, ***P < 0.001). The differences between EV-HDL or EL-HDL (with or without LDL) and LDL (C, D) were analyzed by one-way ANOVA followed by Bonferroni post hoc test (#P < 0.05, ##P < 0.01, ###P < 0.001). w/o, without; w/, with;